Phytochemical Analytical Chemistry & cGMP Standardized Extraction

ODM Raw Material Standardization Manufacturer & Manufacturers

Pioneering botanical reference standards, stoichiometric active-compound validation, and Industry 4.0 contract manufacturing. From phytochemical target isolation to commercial clinical batch release for pharmaceutical, nutraceutical, and cosmetic enterprises.

Validated CRO & CDMO Product Pipeline

Precision Phytochemical Standardization Services

Explore our core laboratory modules and validated technical workflows designed for regulatory compliance across global pharmacopeias.

Establishment of analysis methods of active ingredients
China Establishment of analysis methods of active ingredient(s) Supplier, Suppliers
Explore Analysis Methods
ODM Clinic study Phase1 to Phase 4
ODM Clinic study (Phase1 - Phase 4） Manufacturer, Suppliers
Clinical Study Services
OEM Animal study supplier
OEM Animal study Supplier, Suppliers
Preclinical Animal Testing
China Screening of the active ingredients of plants
China Screening of the active ingredient(s) of plants Manufacturer, Manufacturers
Botanical Screening
OEM In Vitro Test Research Service
OEM In Vitro Test /Research Service Manufacturers, Suppliers
In Vitro Bioassays
Study and evaluation of potency from seasons and origins
ODM Study and evaluation of the potency of the botanical active ingredient(s) from different seasons and different origins. Manufacturer, Suppliers
Origin & Seasonal Potency
Active ingredients screening manufacturer supplier
Botanical Active Ingredients Screening & Molecular Profiling
Screening Discovery
Evaluation for natural materials manufacturer suppliers
Comprehensive Evaluation for Natural Raw Materials & Biomarkers
Material Evaluation
Industrial Authority & Scientific Leadership

The Paradigm Shift in ODM Botanical Raw Material Standardization

Overcoming botanical natural variance through chromatographic fingerprinting, Quality-Marker (Q-Marker) identification, and high-precision cGMP manufacturing.

In the contemporary life-science supply chain, botanical medicines, dietary supplements, and dermo-cosmetic phytocomplexes face an unprecedented challenge: biological heterogeneity. Unlike synthetic small molecules characterized by uniform molecular weights and predictable degradation kinetics, natural botanical raw materials demonstrate substantial fluctuations in secondary metabolite concentrations. Soil microbiome diversity, seasonal temperature deltas, geoclimatic altitude variances, and post-harvest drying dynamics all introduce chemical non-uniformity. MedGence (Yineng Pharma), serving as an institutional Contract Research Organization (CRO) and Contract Development & Manufacturing Organization (CDMO) based in Changsha, China, transforms this inherent natural variability into mathematically verifiable, reproducible chemical standards.
Over 14+ years of dedicated phytochemical pharmacology, MedGence has supported more than 100 top-tier pharmaceutical manufacturers, hospital research networks, and multinational nutraceutical brands. Our technical matrix integrates classical Traditional Chinese Medicine (TCM) formulation legacy with cutting-edge analytical tools—including Ultra-High Performance Liquid Chromatography coupled with Quadrupole Time-of-Flight Mass Spectrometry (UHPLC-QTOF-MS), High-Performance Thin-Layer Chromatography (HPTLC) chemical profiling, and nuclear magnetic resonance (NMR) spectroscopy. Having completed deep scientific validations on 83 classic TCM formulas, engineered 22 innovative natural drug candidates, secured 56 clinical hospital preparation registrations, and benchmarked quality standards for nearly 400 single-herb species, our standardization platform represents an authoritative bridge between raw agricultural botany and FDA/EMA-compliant active pharmaceutical ingredients (APIs).

Quantitative Q-Marker Identification

We transcend generic single-compound assays by deploying multidimensional Quality-Markers (Q-Markers) that correlate directly with physiological bioefficacy, establishing specific chemical fingerprints across every extraction lot.

Contaminant Elimination at Scale

Comprehensive mitigation protocols utilizing Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and GC-MS/MS to guarantee sub-ppm thresholds for heavy metals, polycyclic aromatic hydrocarbons (PAHs), and over 500 pesticide residues.

Full-Chain IP & Formulation Security

Operated strictly under entrusted custom research and CDMO frameworks. Intellectual property, solvent selectivity ratios, and proprietary thermal profiles remain protected under rigorous non-disclosure agreements.

Phytochemical Market Intelligence

Global Raw Material Standardization Trends & Enterprise Procurement

How regulatory stringency across North America, the European Union, and Asia-Pacific is redefining the procurement specifications of Fortune 500 nutraceutical and pharmaceutical corporations.

The international phytomedicine and standardized extract sector is experiencing a structural migration from commoditized dry plant extracts toward therapeutically quantified, multi-constituent phytocomplexes. Global regulatory bodies—specifically the US FDA (under 21 CFR Part 111 for dietary supplements and 21 CFR Part 314/Botanical Drug Guidance), the European Medicines Agency (EMA/HMPC monographs), and the World Health Organization (WHO Guidelines on Good Agricultural and Collection Practices)—have systematically tightened analytical acceptance criteria.
Procurement Dimension Legacy Extract Sourcing MedGence ODM Standardization Framework Compliance Advantage
Botanical Identity Verification Macroscopic inspection, basic TLC visual comparison. Orthogonal DNA barcoding, HPTLC high-resolution fingerprinting, and digital reference spectra matching. Zero Adulteration Risk Complete protection against economically motivated species substitution.
Potency Standardization Single-marker photometric UV assay (vulnerable to non-specific absorbance). Multi-wavelength HPLC-DAD, UPLC-ELSD, and LC-MS/MS quantification of active metabolite families. RSD < 2.0% Rigorous batch-to-batch repeatability and predictable clinical dosing.
Trace Toxicological Screening Non-specific spot testing or periodic supplier self-declarations. Batch-specific ICP-MS heavy metals (Pb, As, Cd, Hg), GC-MS/MS 500+ pesticide residue screen, aflatoxins B1/B2/G1/G2, and pyrrolizidine alkaloids. USP <561> / EP 2.8.13 Full alignment with European and United States Pharmacopeia standards.
Batch-to-Batch Variance Potency fluctuations ranging from ±25% to ±40% across seasonal harvests. Micro-engineered physical blending, stoichiometric active normalization, and standardized extraction yields. Seamless Formulations Eliminates viscosity, dissolution, and bioavailability discrepancies in finished capsules/tablets.
Environmental & Supply Resilience Fragmented broker networks with zero traceability to origin or harvest timing. Digitally mapped geographic sourcing, geo-origin potency benchmarking, and direct vertical factory processing. Supply Chain ESG Continuous audit-ready traceability from cultivation farm gate to industrial release.
Corporate procurement teams now evaluate contract manufacturers not merely on per-kilogram price points, but on Total Quality Cost (TQC). A substandard lot that fails microbial endotoxin assays, contains unexpected solvent residues (e.g., class 1 or class 2 solvents violating USP <467>), or demonstrates broad chromatogram deviations can force complete product recalls, regulatory warning letters, or catastrophic delays in New Drug Applications (NDA). MedGence's ODM raw material standardization process acts as a robust risk-insulation barrier for multinational pharmaceutical and nutritional buyers.
Smart Manufacturing & Supply Chain Resilience

China Factory 4.0: High-Efficiency Botanical Extraction Architecture

Harnessing automated Distributed Control Systems (DCS), continuous countercurrent extraction, and green industrial chemistry to guarantee global supply security.

14+
Years Dedicated Natural Medicine CRO/CDMO
300+
In-House Research Scientists & Analytical Chemists
83
Classic TCM Formulations Fully Modernized
~400
Single-Herb Pharmacopeial Standards Engineered

Continuous Countercurrent Extraction

Maximizes active compound partition coefficients while lowering thermal degradation risks. Achieves a 94.8% average extraction efficiency compared to conventional static maceration.

PAT & Automated DCS Process Loops

Real-time Process Analytical Technology (PAT) coupled with NIR inline sensors tracks critical quality attributes (CQAs) at extraction, column filtration, and vacuum evaporation phases.

Supercritical CO2 & Ceramic Membrane Fractionation

Green solvent systems eliminating toxic organic residues. Multi-stage ceramic micro- and ultra-filtration removes inactive tannins and heavy proteins, yielding clean, crystallized actives.

Supply Chain Redundancy & Scale

Direct logistical linkage with certified agricultural cultivation zones across China ensures raw herb reserve buffers, shielding partners from global geopolitical and climate-related supply shocks.

Regulatory Harmonization & Regional Compliance

Localized Application Scenarios: North America, EU, and APAC

Customizing extraction chemistry, documentation dossiers, and analytical testing to pass local regulatory gates seamlessly.

North America: US FDA 21 CFR 111 & Botanical Drug NDA

In the United States, dietary supplements demand rigorous compliance with cGMP 21 CFR 111, requiring 100% identity verification for raw botanical components before blending. MedGence delivers complete Certificate of Analysis (COA) packages with verified chromatograms. For innovators pursuing the FDA Botanical Drug route (21 CFR Part 314), our Changsha labs supply CMC (Chemistry, Manufacturing, and Controls) documentation, batch-to-batch chromatographic overlay data, and preclinical toxicology packages (LD50, acute, chronic, Ames genotoxicity) necessary to clear Investigational New Drug (IND) hurdles.

European Union: EMA/HMPC Monograph Alignment

European Union markets enforce some of the world's most restrictive contaminant ceilings under Regulation (EC) No 1881/2006 (and subsequent updates for PAHs, cadmium, and pyrrolizidine alkaloids). For clients seeking Traditional Herbal Medicinal Product (THMPD) registration under Directive 2004/24/EC or Well-Established Use applications, MedGence provides validated Drug Master File (DMF) components, Drug Extract Ratio (DER) calculations, stability profiles according to ICH Q1A(R2) guidelines, and validated fingerprint assays matching European Pharmacopoeia (Ph. Eur.) monographs.

Asia-Pacific: Chinese Pharmacopoeia & Kampo Standards

Within APAC, standardized herbal extracts form the baseline for both Traditional Chinese Medicine formula granules and Japanese Kampo formulations. Our Changsha facility operates with native fluency in Chinese Pharmacopoeia (ChP) standards, providing specialized decoction-piece extraction, volatile oil retention technologies, and water-soluble granule optimization. This facilitates smooth entry into hospital dispensaries, national health insurance formularies, and high-growth Asian functional food sectors.

End-to-End CDMO Integration

From Standardized Bulk Intermediates to Commercial Dosage Forms

Eliminate intermediate handoff losses and technical transfer risks with our unified research-to-manufacturing infrastructure.

Standardized Active Powders

Spray-dried and vacuum-belt-dried botanical extracts with uniform particle mesh distribution (80 to 200 mesh), customized bulk densities, and optimized hygroscopic profiles for direct capsule filling.

High-Potency Concentrates & Pastes

Low-temperature falling film evaporators maintain native secondary metabolite structures, yielding viscous herbal pastes and oleoresins with tight water activity (Aw < 0.6) controls.

Finished Solid Dosage Forms

cGMP contract packaging across vegetarian (HPMC) and gelatin capsules, enteric-coated softgels, bi-layer functional tablets, effervescent granules, and micro-pellets with controlled release kinetics.

Sterile & Oral Liquid Solutions

Modernized oral tonic liquids, nano-emulsion botanical drops, and sublingual sprays utilizing ultra-clean CIP/SIP sterilization and validated preservative-free packaging lines.

Technical & Procurement FAQ

Frequently Asked Questions on Botanical ODM Standardization

Detailed insights from our chief analytical chemists and regulatory affairs directors.

What specifically distinguishes MedGence's ODM Raw Material Standardization from conventional herbal extracts?
Conventional herbal extracts are typically produced through generic hydroalcoholic boiling and standardized against a single, easily isolated marker compound—frequently using non-selective UV spectrophotometry that can be spoofed by common adulterants. MedGence's ODM standardization employs multi-marker chromatographic fingerprinting (HPTLC, HPLC-DAD, LC-MS/MS). We identify and quantify entire families of bioactive metabolites (e.g., total ginsenosides, specific astragalosides, bioactive flavonoid glycosides) while validating biological relevance through in vitro bioassays. Crucially, our extraction methods lock in stoichiometric ratios, ensuring that every batch exhibits identical bioactivity and dissolution kinetics regardless of natural harvest variations.
How does your technical team address origin and seasonal potency variations?
We operate proprietary geographic and seasonal screening protocols. Because secondary metabolite accumulation correlates with soil composition, UV exposure, altitude, and seasonal dormancy, we evaluate specimens across diverse ecological regions and multiple harvest stages (spring vs. autumn, wild-crafted vs. GAP-cultivated). Using chemometric statistical analysis (such as Principal Component Analysis, PCA), we identify the optimal sourcing terroir and harvesting window. If raw feedstock still fluctuates, our precision pilot facility uses standardized stoichiometric blending of qualified lots before extraction to maintain tight finished-potency specifications within a target Relative Standard Deviation (RSD) of less than 2.0%.
Can you support Investigational New Drug (IND) and New Drug Applications (NDA) for botanical pharmaceuticals?
Yes. MedGence possesses a validated track record of developing 22 innovative natural medicines and modernizing 83 classic TCM formulations. We generate complete Chemistry, Manufacturing, and Controls (CMC) dossiers, establish validated analytical assays compliant with ICH Q2(R1) guidelines, conduct accelerated and long-term stability studies (ICH Q1A), and perform full-scale preclinical toxicology suites (GLP-compliant acute oral LD50, 90-day subchronic toxicity, Ames bacterial reverse mutation, and in vivo micronucleus assays). Furthermore, our clinical trial division coordinates Phase I through Phase IV human trials to generate statistical evidence acceptable to national drug agencies.
How are proprietary formulas, novel extraction parameters, and client IP protected?
Intellectual property security is central to our entrusted research and CDMO business model. Prior to any scientific exchange, enforceable Non-Disclosure Agreements (NDAs) are established under your preferred international legal jurisdiction. Production parameters—such as solvent ratios, resin elution gradients, temperature curves, and micronization techniques—are segregated within dedicated digital networks. Production campaigns can be conducted on dedicated manufacturing lines with strict access control, ensuring your commercial formulations are never exposed, reverse-engineered, or distributed to third parties.
What contaminant screening thresholds and pharmacopeial monographs do you routinely validate against?
Every standardized production lot undergoes rigorous screening in our central testing laboratory. We test in strict accordance with United States Pharmacopeia (USP <561> Articles of Botanical Origin, <2232> Elemental Contaminants), European Pharmacopoeia (EP 2.8.13 Pesticide Residues, EP 2.8.18 Heavy Metals), and Chinese Pharmacopoeia (ChP Rule 9302). Contaminant analyses encompass over 500 multi-residue pesticides via GC-MS/MS and LC-MS/MS, toxic heavy metals (Lead < 0.5 ppm, Cadmium < 0.3 ppm, Arsenic < 1.0 ppm, Mercury < 0.1 ppm via ICP-MS), total aflatoxins (< 4 ppb) and Ochratoxin A via immunoaffinity HPLC, microbial limits (USP <2021> / <2022>), and residual solvents via headspace gas chromatography (USP <467>).
What are the minimum order quantities (MOQs) and pilot-scale lead times?
Because we operate integrated pilot research facilities alongside full commercial CDMO factories, our capacity scales flexibly. For custom active ingredient screening and extraction method establishment, pilot trial runs can begin with bench-scale quantities (5 kg to 50 kg of raw botanical material). Commercial manufacturing batches for customized standardized extracts generally feature an MOQ of 100 kg to 500 kg depending on target active concentration. Standard analytical method validation requires approximately 3 to 5 weeks, while commercial pilot extraction runs typically conclude within 4 to 6 weeks from raw material qualification.
Commercial Service Portfolio

Select an ODM Botanical Standardization Module

Accelerate your clinical drug development or high-potency nutraceutical commercialization with our validated research capabilities.

Establishment of analysis methods of active ingredients
China Establishment of analysis methods of active ingredient(s) Supplier, Suppliers
Analytical Method Setup
ODM Clinic study Phase1 to Phase 4
ODM Clinic study (Phase1 - Phase 4） Manufacturer, Suppliers
Clinical Study Packages
OEM Animal study supplier
OEM Animal study Supplier, Suppliers
Animal Efficacy Models
China Screening of active ingredients of plants
China Screening of the active ingredient(s) of plants Manufacturer, Manufacturers
High-Throughput Screening
OEM In Vitro Test Research Service
OEM In Vitro Test /Research Service Manufacturers, Suppliers
Cell Assays & Screening
Evaluation of potency from seasons and origins
ODM Study and evaluation of the potency of the botanical active ingredient(s) from different seasons and different origins. Manufacturer, Suppliers
Terroir & Harvest Studies
Analysis method establishing supplier
Chromatographic Fingerprint & Analytical Method Validation
Fingerprint Validation
Clinic study manufacturers supplier
Phase I–IV Clinical Trial Design & Human Pharmacokinetics
Clinical Research CRO
[ Entrusted Custom CRO/CDMO Engagement ]

Initiate Your Standardized Active Ingredient Project

Connect directly with our scientific committee in Changsha to discuss botanical biomarker identification, custom pilot extraction parameters, or ICH-compliant analytical validation dossiers.

Email Technical Directorate Contact Headquarters